Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
NOVATO, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer, will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015 at 8:35am ET in New York.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
